Quince Therapeutics announced that the FDA has granted Fast Track designation for its EryDex System for the treatment of patients with Ataxia-Telangiectasia, or A-T. EryDex is comprised of dexamethasone sodium phosphate, or DSP, encapsulated in a patient’s own red blood cells utilizing Quince’s proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform. DSP is a corticosteroid well known for its anti-inflammatory properties as well as its dose-limiting toxicity due to adrenal suppression. EryDex is designed to provide the efficacy of corticosteroids and to reduce or eliminate the significant adverse effects that accompany chronic corticosteroid treatment.